Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?

Rev Neurol (Paris). 2022 Mar;178(3):266-267. doi: 10.1016/j.neurol.2021.06.012. Epub 2021 Sep 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aspergillosis* / drug therapy
  • Aspergillosis* / etiology
  • Crotonates / adverse effects
  • Humans
  • Hydroxybutyrates
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / complications
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Nitriles
  • Toluidines / adverse effects

Substances

  • Crotonates
  • Hydroxybutyrates
  • Nitriles
  • Toluidines
  • teriflunomide